Hydroxocobalamin/ja

Hydroxocobalamin/ja

Clinical data
Other names	vitamin B12, vitamin B12a, hydroxycobalamin
AHFS/Drugs.com	Monograph
MedlinePlus	a605007
Routes of administration	Intramuscular, intravenous/ja
ATC code	B03BA03 (WHO) V03AB33 (WHO)
Legal status
Legal status	US: OTC (注射の場合は処方箋による）、DEA規制外
Pharmacokinetic data
Protein binding	Very high (90%)
Metabolism	主に肝臓で、コバラミンは回腸で吸収され、肝臓に貯蔵される。
Elimination half-life	~6 days
Identifiers
IUPAC name Coα-[α-(5,6-dimethylbenzimidazolyl)]- Coβ-hydroxocobamide
CAS Number	13422-51-0 Y
PubChem CID	6433575
DrugBank	DB00200
ChemSpider	28534326
UNII	Q40X8H422O
KEGG	D01027
ChEBI	CHEBI:27786
ChEMBL	ChEMBL1237097
Chemical and physical data
Formula	C62H89CoN13O15P
Molar mass	1346.377 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc1cc2ncn(c2cc1C)C9OC(CO)C(OP3(=O)OC(C)CNC(=O)CCC5C4=C(C)C8=NC(=CC7=NC(=C(C)C6=NC(C)(C(N4[Co](O)O3)C5(C)CC(N)=O)C(C)(CC(N)=O)C6CCC(N)=O)C(C)(CC(N)=O)C7CCC(N)=O)C(CCC(N)=O)C8(C)C)C9O
InChI InChI=1S/C62H90N13O14P.Co.H2O/c1-29-20-40-41(21-30(29)2)75(28-70-40)56-52(84)53(42(27-76)87-56)89-90(85,86)88-31(3)26-69-49(83)19-15-36-50-32(4)54-58(6,7)34(12-16-43(63)77)38(71-54)22-39-35(13-17-44(64)78)59(8,23-46(66)80)55(72-39)33(5)51-37(14-18-45(65)79)61(10,25-48(68)82)62(11,74-51)57(73-50)60(36,9)24-47(67)81;;/h20-22,28,31,34-37,42,52-53,56-57,76,84H,12-19,23-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);;1H2/q;+3;/p-3 Y Key:GTSMWDDKWYUXGH-UHFFFAOYSA-K Y
NY (what is this?)  (verify)

ヒドロキソコバラミン（hydroxocobalamin）は、ビタミンB_12aやヒドロキシコバラミンとしても知られるビタミンの一種で、食品中に含まれ、栄養補助食品として用いられる。サプリメントとしては、悪性貧血を含むビタミンB12欠乏症の治療に用いられる。その他の用途としては、シアン中毒、レーバー視神経萎縮症、中毒性弱視の治療がある。筋肉内または静脈内に注射する。

副作用は一般的にほとんどない。下痢、気分の悪さ、ほてり、かゆみ、低血中カリウム、アレルギー反応、高血圧などである。通常量は妊娠中に安全と考えられている。この薬物による過量投与や毒性は報告されていない。ヒドロキソコバラミン（hydroxocobalamin）は、ビタミンB₁₂の天然型であり、化合物のコバラミンファミリーのメンバーである。ヒドロキソコバラミン、またはビタミンB₁₂の別の形態は、体内でDNAを作るために必要である。

ヒドロキソコバラミンは1949年に初めて単離された。WHO必須医薬品リストに掲載されている。ヒドロキソコバラミンはジェネリック医薬品として販売されている。

Medical uses

Hydroxocobalamin at standard conditions is a solid composed of dark red crystals.

Hydroxocobalamin injection USP (1000 μg/mL) is a clear red liquid solution. Shown is 500 μg B-12 prepared for subcutaneous injection.

Vitamin B₁₂ deficiency

Standard therapy for treatment of vitamin B₁₂ deficiency has been intramuscular (IM) or intravenous (IV) injections of hydroxocobalamin (OHCbl), since the majority of cases are due to malabsorption by the enteral route (gut). It is used pediatric patients with intrinsic cobalamin metabolic diseases, vitamin B₁₂-deficient patients with tobacco amblyopia due to cyanide poisoning, and patients with pernicious anemia who have optic neuropathy.

In a newly diagnosed vitamin B₁₂-deficient patient, normally defined as when serum levels are less than 200 pg/ml, daily IM injections of hydroxocobalamin up to 1,000 μg (1 mg) per day are given to replenish the body's depleted cobalamin stores. In the presence of neurological symptoms, following daily treatment, injections up to weekly or biweekly are indicated for six months before initiating monthly IM injections. Once clinical improvement is confirmed, maintenance supplementation of B₁₂ will generally be needed for life.

Cyanide poisoning

Hydroxocobalamin is first line therapy for people with cyanide poisoning. Hydroxocobalamin converts cyanide to the much less toxic cyanocobalamin. Cyanocobalamin is renally cleared. The use of hydroxocobalamin became first line due to its low adverse risk profile, rapid onset of action, and ease of use in the prehospital setting.

Injectable hydroxocobalamin

Injection of hydroxocobalamin is used to rectify the following causes of vitamin B₁₂ deficiency (list taken from the drug prescription label published by the U.S. Food and Drug Administration)

• Dietary deficiency of vitamin B₁₂ occurring in strict vegetarians and in their breastfed infants (isolated vitamin B₁₂ deficiency is very rare)
• Malabsorption of vitamin B₁₂ resulting from damage to the stomach, where intrinsic factor is secreted, or damage to the ileum, where intrinsic factor facilitates vitamin B₁₂ absorption. These conditions include tropical sprue and nontropical sprue (celiac disease).
• Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (which can be caused by ingestion of corrosives, extensive tumors, and conditions associated with gastric atrophy, such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy)
• Structural lesions leading to vitamin B₁₂ deficiency, including regional ileitis, ileal reactions, and malignancies
• Competition for vitamin B₁₂ by intestinal parasites or bacteria. The tapeworm from undercooked fish (Diphyllobothrium latum) absorbs huge quantities of vitamin B₁₂, and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B₁₂ or folate.
• Inadequate use of vitamin B₁₂, which may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia

Pernicious anemia is the most common cause of vitamin B₁₂ deficiency. While it technically refers to anemia caused specifically by autoimmune deficiency of intrinsic factor, it is commonly used to refer to B₁₂-deficient anemia as a whole, regardless of cause.

Side effects

The literature data on the acute toxicity profile of hydroxocobalamin show it is generally regarded as safe with local and systemic exposure. The ability of hydroxocobalamin to rapidly scavenge and detoxify cyanide by chelation has resulted in several acute animal and human studies using systemic hydroxocobalamin doses at suprapharmacological doses as high as 140 mg/kg to support its use as an intravenous (IV) treatment for cyanide exposure. The US FDA at the end of 2006 approved the use hydroxocobalamin as an injection for the treatment of cyanide poisoning.

The drug causes a reddish discoloration of the urine (chromaturia), which can look like blood in the urine.

Properties

Hydroxocobalamin acetate occurs as odorless, dark-red orthorhombic crystals. The injection formulations appear as clear, dark-red solutions. It has a distribution coefficient of 1.133×10^⁻⁵ and a pKa of 7.65.

Mechanism of action

Vitamin B₁₂ refers to a group of compounds called cobalamins that are available in the human body in a variety of mostly interconvertible forms. Together with folate, cobalamins are essential cofactors required for DNA synthesis in cells where chromosomal replication and division are occurring—most notably the bone marrow and myeloid cells. As a cofactor, cobalamins are essential for two cellular reactions:

• the mitochondrial methylmalonyl-CoA mutase conversion of methylmalonic acid (MMA) to succinate, which links lipid and carbohydrate metabolism, and
• the activation of methionine synthase, which is the rate-limiting step in the synthesis of methionine from homocysteine and 5-methyltetrahydrofolate.

Cobalamins are characterized by a porphyrin-like corrin nucleus that contains a single cobalt atom bound to a benzimidazolyl nucleotide and a variable residue (R) group. The variable R group gives rise to the four most commonly known cobalamins: CNCbl, methylcobalamin, 5-deoxyadenosylcobalamin, and OHCbl. In the serum, hydroxocobalamin and cyanocobalamin are believed to function as storage or transport forms of the molecule, whereas methylcobalamin and 5-deoxyadenosylcobalamin are the active forms of the coenzyme required for cell growth and replication. Cyanocobalamin is usually converted to hydroxocobalamin in the serum, whereas hydroxocobalamin is converted to either methylcobalamin or 5-deoxyadenosyl cobalamin. Cobalamins circulate bound to serum proteins called transcobalamins (TC) and haptocorrins. Hydroxocobalamin has a higher affinity to the TC II transport protein than cyanocobalamin, or 5-deoxyadenosylcobalamin. From a biochemical point of view, two essential enzymatic reactions require vitamin B₁₂ (cobalamin).

Intracellular vitamin B₁₂ is maintained in two active coenzymes, methylcobalamin and 5-deoxyadenosylcobalamin. In the face of vitamin B₁₂ deficiency, conversion of methylmalonyl-CoA to succinyl-CoA cannot take place, which results in accumulation of methylmalonyl-CoA and aberrant fatty acid synthesis. In the other enzymatic reaction, methylcobalamin supports the methionine synthase reaction, which is essential for normal metabolism of folate. The folate-cobalamin interaction is pivotal for normal synthesis of purines and pyrimidines and the transfer of the methyl group to cobalamin is essential for the adequate supply of tetrahydrofolate, the substrate for metabolic steps that require folate. In a state of vitamin B₁₂ deficiency, the cell responds by redirecting folate metabolic pathways to supply increasing amounts of methyltetrahydrofolate. The resulting elevated concentrations of homocysteine and MMA are often found in patients with low serum vitamin B₁₂ and can usually be lowered with successful vitamin B₁₂ replacement therapy. However, elevated MMA and homocysteine concentrations may persist in patients with cobalamin concentrations between 200 and 350 pg/mL. Supplementation with vitamin B₁₂ during conditions of deficiency restores the intracellular level of cobalamin and maintains a sufficient level of the two active coenzymes: methylcobalamin and deoxyadenosylcobalamin.